COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders (CNPs), today announced the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for evaluation of COUR's CNP-201 in a proof-of-concept (Phase 1 / 2) study in people who are allergic to peanuts.
Kids With Food Allergies (KFA) , a division of the Asthma and Allergy Foundation of America , hosted a webinar with Sloane Miller, MFA, MSW, LMSW, called Food Allergy Confidence During the Holidays. View video on YouTube Ms. Miller...
When you block a person, they can no longer invite you to a private message or post to your profile wall. Replies and comments they make will be collapsed/hidden by default. Finally, you'll never receive email notifications about content they create or likes they designate for your content.
Note: if you proceed, you will no longer be following .